<DOC>
	<DOCNO>NCT00110305</DOCNO>
	<brief_summary>The purpose study evaluate dose-response relationship antiviral activity 48 week treatment 3 different dose regimen TMC278 .</brief_summary>
	<brief_title>A Study TMC278 Human Immunodeficiency Virus Type 1 Infected Patients , Who Are Not Treated With Antiretroviral Medicines</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , active control ( participant assign either recognize effective treatment study medication ) study . This study consist 3 phase : screening phase ( 4 week ) , treatment phase ( 96 week ) , follow phase ( 4 week ) . In treatment phase , participant randomly assign 1 4 treatment group : ( 1 ) TMC278 25 mg , ( 2 ) TMC278 75 mg , ( 3 ) TMC278 150 mg , ( 4 ) efavirnez ( control group ) ; along investigator select 2 non-nucleoside reverse transcriptase inhibitor ( NRTIs ) Week 96 . TMC278 assign double-blinded fashion ( participant investigator aware TMC278 dose participant receive ) efavirnez assign open-label fashion ( people know treatment participant receive ) . After Week 96 , 3 optional open-label ( people know identity intervention ) extension period conduct collect long term safety effectiveness data TMC278 . 3 optional extension period : first optional extension period ( participant receive TMC278 75 mg + 2 NRTIs Week 96 Week144 ) ; second optional extension period ( participant receive TMC278 25 mg + 2 NRTIs Week 144 Week 240 ) ; third optional extension period ( participant receive TMC278 25 mg + 2 NRTIs Week 240 TMC278 commercially available ) . Participants efavirenz group option continue efavirenz + 2 NRTIs total treatment duration 240 week . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , physical examination , vital sign monitor throughout study . The maximum duration study 104 , 152 , 248 week , plus optional third extension period .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Documented human immunodeficiency virus type 1 ( HIV1 ) infection Never treat antiretroviral ( ARV ) treatment therapeutic HIV vaccine , receive less equal 2 week treatment prior screen nucleoside reverse transcriptase inhibitor HIV1 plasma viral load 5000 HIV1 RNA copy per milliliter , screen Cortisol least 550 nano mole per liter ( 19.9 microgram per deciliter ) screen Sensitivity investigator select nucleoside , screen Currently active Acquired Immunodeficiency Syndrome ( AIDS ) define illness Known suspect acute ( primary ) HIV1 infection Any current history adrenal disorder , acute hepatitis A , B , C infection Documented genotypic evidence NonNucleoside Reverse Transcriptase Inhibitor ( NNRTI ) resistance screen Pregnant breastfeed female Not agree protocoldefined effective use contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Human Immunodeficiency Virus Type 1</keyword>
	<keyword>Human immunodeficiency virus ( HIV )</keyword>
	<keyword>Antiretroviral</keyword>
	<keyword>Antiviral</keyword>
	<keyword>ARV</keyword>
	<keyword>TMC278</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Combivir</keyword>
	<keyword>Truvada</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Tenofovir disoproxil fumarate</keyword>
	<keyword>Emtricitabine</keyword>
</DOC>